{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=59&state=Indiana",
    "query": {
      "state": "Indiana",
      "city": "Indianapolis",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 8625,
    "total_pages": 863,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=60&state=Indiana&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=58&state=Indiana&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:44:16.681Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05850325",
      "title": "Novel Exercises to Facilitate Recovery of Supination and Pronation for Distal Radius Fractures Managed With a Volar Plate",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Distal Radius Fracture"
      ],
      "interventions": [
        {
          "name": "Group 1 Elbow Flexed at 90 Degrees",
          "type": "OTHER"
        },
        {
          "name": "Group 2 Elbow Fully Flexed",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana Hand to Shoulder Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-12-16",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850325"
    },
    {
      "nct_id": "NCT00973817",
      "title": "Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute On Chronic Hepatitis"
      ],
      "interventions": [
        {
          "name": "ELAD plus standard of care treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vital Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "18 Years to 67 Years"
      },
      "enrollment_count": 62,
      "start_date": "2009-09",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-04-08",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973817"
    },
    {
      "nct_id": "NCT00846547",
      "title": "Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "Arbaclofen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seaside Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 32,
      "start_date": "2009-02",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2013-06-14",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00846547"
    },
    {
      "nct_id": "NCT02230917",
      "title": "A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Silbermann",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230917"
    },
    {
      "nct_id": "NCT03737851",
      "title": "A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "elezanumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 208,
      "start_date": "2018-12-11",
      "completion_date": "2021-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Hanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737851"
    },
    {
      "nct_id": "NCT03011372",
      "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-04-25",
      "completion_date": "2024-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Duarte, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011372"
    },
    {
      "nct_id": "NCT05637801",
      "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease 1",
        "Alzheimer Disease 2",
        "Alzheimer Disease 3",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Alzheimer Disease 9",
        "Alzheimer Disease 4",
        "Alzheimer Disease 7",
        "Alzheimer Disease 17",
        "Alzheimer's Dementia Late Onset",
        "Alzheimer Disease 5",
        "Alzheimer Disease 6",
        "Alzheimer Disease 8",
        "Alzheimer Disease 10",
        "Alzheimer Disease 11",
        "Alzheimer Disease 12",
        "Alzheimer Disease 13",
        "Alzheimer Disease 14",
        "Alzheimer Disease 15",
        "Alzheimer Disease 16",
        "Alzheimer Disease 18",
        "Alzheimer Disease 19",
        "Dementia",
        "Dementia Alzheimers",
        "Dementia, Mild",
        "Dementia of Alzheimer Type",
        "Dementia Moderate",
        "Dementia Senile",
        "Mild Cognitive Impairment",
        "Mild Dementia",
        "MCI",
        "Cognitive Impairment",
        "Cognitive Decline",
        "Cognitive Impairment, Mild"
      ],
      "interventions": [
        {
          "name": "Spectris™ AD - Active",
          "type": "DEVICE"
        },
        {
          "name": "Spectris™ AD - Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cognito Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 673,
      "start_date": "2022-12-13",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 68,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05637801"
    },
    {
      "nct_id": "NCT00404001",
      "title": "Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "MD-0727",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ironwood Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2006-11",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-10-01",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404001"
    },
    {
      "nct_id": "NCT06819007",
      "title": "Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 582,
      "start_date": "2025-03-19",
      "completion_date": "2032-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 33,
      "location_summary": "Burbank, California • La Jolla, California • Palo Alto, California + 26 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819007"
    },
    {
      "nct_id": "NCT00066456",
      "title": "Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Chemosensitization/Potentiation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-02-11",
      "last_synced_at": "2026-11-19T09:44:16.681Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066456"
    }
  ]
}